Accumulate Sun Pharma with 18-24 months view: Devang Mehta

Devang Mehta of Anand Rathi Financial Services told CNBC-TV18, "These are times when investors need to understand that the integration of Sun Pharmaceutical Industries with Ranbaxy Laboratories is going to take its own sweet time. It will also have an impact on the financials of Sun Pharma for sure. The company has been quite vocal about, talking about that as well as the problems that are persisting at the Halol plant.""There can be some downside for short and medium-term traders; should be aware of down fall in the stock may be in the near term but somebody who has a investing horizon of about 18-24 months, this is a good stock to start again accumulating," he said.